{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8"}]}],"title":"Clinical benefit rates"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"}]}],"title":"Response rates"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scan","groups":[{"description":"trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1\n\ntrientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)\n\npegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1\n\ncarboplatin: carboplatin AUC 4 IV D1","id":"OG000","title":"Trientine With Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Two participants who declined any of the study agents after enrollment or declined the initial chemotherapy drug after a 7-day course of trientine were deemed ineligible for this analysis. According the protocol for this secondary outcome, all participants were not described separately.","reportingStatus":"POSTED","timeFrame":"176 days","title":"Percentage of Participants With Measurable Tumor Treatment Response Assessed by RECIST Criteria 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}